Evidence map›Paper›PMID 29968677›Full record

ArticleActa crystallographica. Section D, Structural biology2018

The structure of the C-terminal domain of the nucleoprotein from the Bundibugyo strain of the Ebola virus in complex with a pan-specific synthetic Fab.

Malwina J Radwańska, Mateusz Jaskółowski, Elena Davydova, Urszula Derewenda, Tsuyoshi Miyake, Daniel A Engel, Anthony A Kossiakoff, Zygmunt S Derewenda

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Malwina J RadwańskaDepartment of Molecular Physiology and Biological Physics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Mateusz JaskółowskiDepartment of Biochemistry and Molecular Biology, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, IL 60637, USA.
Elena DavydovaDepartment of Biochemistry and Molecular Biology, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, IL 60637, USA.
Urszula DerewendaDepartment of Molecular Physiology and Biological Physics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Tsuyoshi MiyakeDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Daniel A EngelDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Anthony A KossiakoffDepartment of Biochemistry and Molecular Biology, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, IL 60637, USA.
Zygmunt S DerewendaDepartment of Molecular Physiology and Biological Physics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
NCI NIH HHS P30 CA016059U.S. Department of Energy, Office of Biological and Environmental Research DE-AC02-06CH11357U.S. Department of Energy, Office of Science DE-AC02-06CH11357
6 · The paper itself

Abstract

The vast majority of platforms for the detection of viral or bacterial antigens rely on immunoassays, typically ELISA or sandwich ELISA, that are contingent on the availability of suitable monoclonal antibodies (mAbs). This is a major bottleneck, since the generation and production of mAbs is time-consuming and expensive. Synthetic antibody fragments (sFabs) generated by phage-display selection offer an alternative with many advantages over Fabs obtained from natural antibodies using hybridoma technology. Unlike mAbs, sFabs are generated using phage display, allowing selection for binding to specific strains or for pan-specificity, for identification of structural epitopes or unique protein conformations and even for complexes. Further, they can easily be produced in Escherichia coli in large quantities and engineered for purposes of detection technologies and other applications. Here, the use of phage-display selection to generate a pan-specific Fab (MJ20), based on a Herceptin Fab scaffold, with the ability to bind selectively and with high affinity to the C-terminal domains of the nucleoproteins (NPs) from all five known strains of the Ebola virus is reported. The high-resolution crystal structure of the complex of MJ20 with the antigen from the Bundibugyo strain of the Ebola virus reveals the basis for pan-specificity and illustrates how the phage-display technology can be used to manufacture suitable Fabs for use in diagnostic or therapeutic applications.

Indexed as

Antigen-Antibody ComplexCell Surface Display TechniquesCrystallography, X-RayEbolavirusHumansImmunoglobulin Fab FragmentsImmunoglobulin FragmentsNucleoproteinsPeptide LibraryProtein BindingProtein DomainsAntigen-Antibody ComplexImmunoglobulin Fab FragmentsImmunoglobulin FragmentsNucleoproteinsPeptide Libraryantibody–antigen interactionEbola virus Bundibugyo strainEbola virus nucleoproteinFab structuresynthetic antibody fragments

Identifiers

PMID29968677
PMCPMC6038385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.